tetrandrine has been researched along with Cancer of Ovary in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Choi, EJ; Choi, SU; Jung, NP; Kim, HS; Kim, KH; Kim, S; Lee, CO; Park, SH; Park, WK; Zhang, YH | 1 |
| Du, Y; Wang, C; Wang, H; Wang, K; Zhang, J; Zhang, Y | 1 |
2 other study(ies) available for tetrandrine and Cancer of Ovary
| Article | Year |
|---|---|
The bisbenzylisoquinoline alkaloids, tetrandine and fangchinoline, enhance the cytotoxicity of multidrug resistance-related drugs via modulation of P-glycoprotein.
Topics: Alkaloids; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Benzylisoquinolines; Cell Survival; Colorectal Neoplasms; Dactinomycin; Drug Resistance, Multiple; Drug Screening Assays, Antitumor; Drugs, Chinese Herbal; Female; Humans; Isoquinolines; Molecular Structure; Ovarian Neoplasms; Verapamil | 1998 |
Combination of Tetrandrine with cisplatin enhances cytotoxicity through growth suppression and apoptosis in ovarian cancer in vitro and in vivo.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzylisoquinolines; Blotting, Western; Cell Cycle; Cell Proliferation; Cisplatin; Drug Synergism; Female; Humans; Immunoenzyme Techniques; In Vitro Techniques; Membrane Potential, Mitochondrial; Mice; Mice, Inbred BALB C; Mice, Nude; Ovarian Neoplasms; Tumor Cells, Cultured | 2011 |